Dr. Lawrence David Wagman, MD

Dr. Wagman practices at City of Hope Upland - HOPD in Upland, California.

Dr. Wagman's NPI, 1720180383, was assigned on September 3, 2006. Dr. Wagman graduated from Vagelos College of Physicians and Surgeons in 1978. Dr. Wagman holds California license G55578.

Dr. Wagman's primary practice is City of Hope Upland - HOPD, at 1100 San Bernardino Rd, Upland, CA 91786.

Dr. Wagman's primary practice is City of Hope Upland - HOPD in Upland, California. Dr. Wagman is also affiliated with San Antonio Regional Hospital. The medical group on file is City of Hope. Dmand AI also links Dr. Wagman to 1 more physician office, 1 group practice or clinic, 1 hospital outpatient department and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wagman practices, 6 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Wagman's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Wagman is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Wagman's licenses on file in 2 states: California and Maryland.

Dmand AI lists cancerous skin growth removal, gallbladder removal and mastectomy among the conditions Dr. Wagman treats.

CMS data shows 344 Medicare services from Dr. Wagman across 6 procedure codes in 2024, for 219 Medicare patients. Medicare paid $43,853 for them.

CMS counts 219 Medicare patients who saw Dr. Wagman in 2024. The largest group is 65 to 74, with 111 patients. 75% of them have cancer, and 75% have high cholesterol. 31% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wagman's median patient age at 66, with 89% women.

In 2024, Dr. Wagman wrote 77 Medicare Part D claims for 42 patients. 94% of them were for generic drugs. CMS names the drug for 33 of them, across 2 drugs with 11 or more claims each, at $99 in total drug cost. In 2023, CMS named 36 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Wagman for performance year 2024, reported as part of a group. Dr. Wagman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 33 procedures of mastectomy by Dr. Wagman, more than 88% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 69 papers to Dr. Wagman, published from 2005 to 2022. 2012 was the busiest year, with 2. The most frequent topics are Liver Neoplasms, Breast Neoplasms and Palliative Care. Dr. Wagman has published most often in Am Surg. Dr. Wagman's most frequent co-authors are David Z. Chu, MD, Lucille Leong, MD and Carey Ann Cullinane, MD.

Dmand AI links Dr. Wagman to 3 clinical trials. Conditions studied include Breast Neoplasms, Carcinoma, Hepatocellular and Triple Negative Breast Neoplasms. St. Joseph Hospital of Orange sponsors the most, 2.

CMS Open Payments shows 51 general payments to Dr. Wagman from 12 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 65% of the total. Medical Device Business Services, Inc. paid the most, $4,038.

Dmand AI lists 6 awards for Dr. Wagman, most recently America's Top Doctors in 2014.

Dr. Wagman graduated from Vagelos College of Physicians and Surgeons in 1978. Dr. Wagman is a member of ACS.

Dr. Wagman is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.